References
- Kawabata A. Gastrointestinal functions of proteinase-activated receptors. Life Sci 2003; 74: 247–54
- Olbe L. Strong activation of PAR-2 receptors: a common trigger for the development of gastrointestinal adenocarcinomas?. Scand J Gastroenterol 2007; 42: 1133–7
- Edebo A. The esophageal mucosa in reflux disease: endoscopic appearance and tissue structure [Thesis]. University of Gothenburg, Sweden; 2007.
- Richter JE. Gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol 2007; 21: 609–31
- Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079–85
- Wild CP, Hardie LJ. Reflux, Barrett's esophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003; 3: 676–84
- Yoshida N, Katada K, Handa O, Takagi T, Kokura S, Naito Y, et al. Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int J Mol Med 2007; 19: 335–40
- Kunzelmann K, Sun J, Markovich D, König J, Mürle B, Mall M, et al. Control of ion transport in mammalian airways by protease activated receptors type 2 (PAR-2). Faseb J 2005; 19: 969–70
- Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-GERDon P, MacNaughton WK, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol 2002; 161: 1903–14
- Yamashita K, Mimori K, Inoue H, Mori M, Sidransky D. A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 2003; 63: 6575–8
- Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023–9
- Edebo A, Vieth M, Tam W, Bruno M, van Berkel AM, Stolte M, et al. Circumferential and axial distribution of esophageal mucosal damage in reflux disease. Dis Esophagus 2007; 20: 232–8
- Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172–80
- Schmidlin F, Amadesi S, Vidil R, Trevisani M, Martinet N, Caughey G, et al. Expression and function of proteinase-activated receptor 2 in human bronchial smooth muscle. Am J Respir Crit Care Med 2001; 164: 1276–81
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54
- Vergnolle N. Review article: Proteinase-activated receptors: novel signals for gastrointestinal pathophysiology [review article]. Aliment Pharmacol Ther 2000; 14: 257–66
- Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 1996; 314: 1009–16
- Nystedt S, Ramakrishnan V, Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J Biol Chem 1996; 271: 14910–5
- Saifeddine M, al-Ani B, Cheng CH, Wang L, Hollenberg MD. Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Br J Pharmacol 1996; 118: 521–30
- Al-Ani B, Saifeddine M, Hollenberg MD. Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle. Can J Physiol Pharmacol 1995; 73: 1203–7
- Hwa JJ, Ghibaudi L, Williams P, Chintala M, Zhang R, Chatterjee M, et al. Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. Circ Res 1996; 78: 581–8
- Emilsson K, Wahlestedt C, Sun MK, Nystedt S, Owman C, Sundelin J. Vascular effects of proteinase-activated receptor 2 agonist peptide. J Vasc Res 1997; 34: 267–72
- Damiano BP, Cheung WM, Santulli RJ, Fung-Leung WP, Ngo K, Ye RD, et al. Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther 1999; 288: 671–8
- Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079–85
- Huang SC. Protease-activated receptor-1 (PAR1) and PAR2 but not PAR4 mediate relaxations in lower esophageal sphincter. Regul Pept 2007; 142: 37–43